Jagsonpal Pharmaceuticals Announces 47th AGM on Sep 18, 2026, via VC/OAVM
Jagsonpal Pharmaceuticals Limited will hold its 47th AGM on September 18, 2026, via Video Conferencing. The Annual Report for FY 2025-26, including the AGM notice, is available online for shareholders.
This is a standard procedural announcement regarding the AGM and does not involve any new financial information, strategic changes, or significant corporate actions that would directly impact the company's stock price or investor decisions in the short term.
The announcement is a routine corporate disclosure regarding the scheduling of the Annual General Meeting and the availability of the Annual Report. It does not contain any new financial results or significant business updates that would warrant a positive or negative sentiment.
Jagsonpal Pharmaceuticals Limited has announced that its 47th Annual General Meeting (AGM) is scheduled to be held on Friday, September 18, 2026, at 03:30 PM IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).
The Company has issued letters to shareholders whose email addresses are not registered, providing a web-link to access the Annual Report for the financial year 2025-26, which includes the Notice of the AGM. The Annual Report and AGM Notice are being sent in electronic mode to members with registered email IDs. Shareholders can access the Annual Report via the provided web-link: https://www.jagsonpal.com/annual-report/. Detailed information regarding e-voting, participation, speaker registration, and dividend is available in the AGM Notice.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.